Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Acceptance-and-commitment therapy acceptable among advanced cancer patients

05 Jan 2019

Among advanced cancer patients, engagement and satisfaction with acceptance-and-commitment therapy (ACT) appears to be high, according to a new study, which also reports the feasibility of a subsequent trial comparing ACT with talking controls (TC).

Researchers performed a feasibility two-arm randomized controlled trial involving 42 patients with advanced cancer, of whom 20 received ACT while 22 were designated as TC. Study outcomes included the feasibility of recruitment, patient retention, and participant attitudes toward the therapy and outcome measures.

In the overall sample, the most common malignancy was breast cancer, diagnosed in 48 percent (n=20). The average age was 62±11.5 years, and majority of the patients were female (74 percent; n=31). Researchers reported recruiting 78 percent of their target, indicating acceptable feasibility. Main barriers included availability of therapists and definitions of participant eligibility.

In comparison, only 43 percent (n=18) of the initial sample were available for data collection at the 3-month follow-up. This proportion was lower than the 60 percent retention target. Reasons for attrition included death, loss to follow-up and decline in patient health.

In terms of attitude, 62 percent (n=26) of the participants attended at least seven sessions and were identified as mostly or fully engaged with the intervention. Moreover, of those who were followed-up at 3 months, 83 percent and 50 percent of the ACT and TC groups, respectively, found the interventions useful.

The present findings indicate that ACT is an acceptable intervention in patients in palliative care, said researchers. To improve feasibility, future efforts should focus on cutting the burden of research.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.